Ertapenem + Vancomycin

Ertapenem + vancomycin is a combination antibiotic therapy that pairs two different classes of antibiotics with complementary mechanisms of action.

Ertapenem is a 1-β methyl-carbapenem antibiotic with a broad spectrum of activity against many Gram-positive and Gram-negative aerobic and anaerobic bacteria. It works by inhibiting cell wall synthesis through binding to penicillin binding proteins (PBPs), particularly PBPs 2 and 3 in Escherichia coli.

Vancomycin is a glycopeptide antibiotic often reserved as a "drug of last resort." It acts by binding to the acyl-D-ala-D-ala portion of the growing peptidoglycan cell wall in Gram-positive bacteria, preventing the formation of cross-links necessary for cell wall strength. This binding inhibits cell wall biosynthesis by preventing incorporation of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG)-peptide subunits into the peptidoglycan matrix.

The combination may be used in certain clinical scenarios, particularly for complicated infections where broader coverage is needed or where there is concern for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia.